[Antitumor activity of cis-dichloro-bis-(alpha-amino acid ester)platinum complexes]

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.

Archiv der Pharmazie·2002

1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.

Archiv der Pharmazie·2001

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice.

Archiv der Pharmazie·2001

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part II. Studies on the influence of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) on the specific immune defense in MXT-M-3,2 breast cancer bearing mice.

Archiv der Pharmazie·2001

[Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.

Journal of cancer research and clinical oncology·2000

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloroplatinum(II) act on the hormone-sensitive, murine breast cancer as a biological response modifier? Part 1: The MXT-M-3.2 breast cancer stimulates the growth of an identical second graft; [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplat inum (II) inhibits this process.

Archiv der Pharmazie·2000

Discovery of Novel Ligands for the Treatment of Cryptococcus neoformans Infection.

Archiv der Pharmazie·2026

BRET-Based Approaches for Ion Channels: Emerging Applications and Future Directions.

Archiv der Pharmazie·2026

First UV-Based Strategies Integrating Whiteness, Greenness, and Blueness Appraisals for Estimating Meloxicam and Tramadol Concurrently in Their Veterinary Mixture.

Archiv der Pharmazie·2026

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Archiv der Pharmazie·2026

Structural Modifications of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): New Horizons in Antimicrobial Drug Discovery.

Archiv der Pharmazie·2026

Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.

Archiv der Pharmazie·2026

Aluminum-based salts: an unorthodox but simple way to treat molluscum contagiosum and cutaneous warts.

F1000Research·2026

Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2026

Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.

Naunyn-Schmiedeberg's archives of pharmacology·2026

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

Urologie (Heidelberg, Germany)·2026

ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression.

Oncogene·2026

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

British journal of haematology·2026

Related Experiment Videos

[Antitumor activity of cis-dichloro-bis-(alpha-amino acid ester)platinum complexes]

Related Concept Videos

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine] dichloroplatinum(II) act as an immune response modifier? IV. Inhibition of the proliferation-increasing effect of progressively growing MXT-M-3,2 breast cancer on phagocytes by the title compound.

1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethanes--new biological response modifiers for the therapy of breast cancer. Synthesis and evaluation of estrogenic/antiestrogenic properties.

Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]- dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F1 mice.

[Aqua-1-(2,6-dichloro-4-hydroxyphenyl)-2-phenylethylenediamine] sulfatoplatinum(II) complexes with variable substituents in the 2-phenyl ring. 3. Investigation of breast cancer inhibiting properties.

Discovery of Novel Ligands for the Treatment of Cryptococcus neoformans Infection.

BRET-Based Approaches for Ion Channels: Emerging Applications and Future Directions.

First UV-Based Strategies Integrating Whiteness, Greenness, and Blueness Appraisals for Estimating Meloxicam and Tramadol Concurrently in Their Veterinary Mixture.

Recent Developments and Structure-Activity Relationships of BRAF Inhibitors for Cancer Drug Discovery.

Structural Modifications of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): New Horizons in Antimicrobial Drug Discovery.

Benzophenone Derivatives as a New Class of Anti-Infectives Against Acanthamoeba spp.

Aluminum-based salts: an unorthodox but simple way to treat molluscum contagiosum and cutaneous warts.

Post-diagnosis cannabis use and its association with health status and quality of life in cancer survivors.

Aloesin mitigates cisplatin-induced nephrotoxicity by suppressing NF-κB-mediated oxidative stress and modulating Bax/Bcl-2/caspase pathways.

[Immune checkpoint inhibition plus Bacillus Calmette-Guerin (BCG) therapy in BCG-naive high-risk non-muscle-invasive bladder cancer: a critical review in the context of current evidence].

ITGA5 promotes homologous recombination mediated radioresistance in esophageal squamous cell carcinoma by upregulating RAD51AP1 expression.

Comparison of venetoclax and azacitidine versus a cytarabine-based treatment for patients with acute myeloid leukaemia in first relapse after chemotherapy. A real-world study of the DATAML-IPC-AURAML consortium.

Related Experiment Videos

[Antitumor activity of cis-dichloro-bis-(alpha-amino acid ester)platinum complexes]

Related Concept Videos

Related Articles